Kairos Pharma Ltd (KAPA) Actualités

Form 8-K - Current report

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced that the company presented preclinical data on...

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that through its academic partnership with...

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. Kairos Pharma Ltd. (NYSE...

Form DEF 14C - Other definitive information statements

Form 8-K - Current report

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company presented a talk during the...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form PRE 14C - Other preliminary information statements

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form D - Notice of Exempt Offering of Securities

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during...

Kairos Pharma Provides Business Update and Outlook into 2025

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug...

Form 8-K - Current report